Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: Implications for its clinical use (pages 2150–2157)
Edoardo G. Giannini, Giorgio Sammito, Fabio Farinati, Francesca Ciccarese, Anna Pecorelli, Gian Lodovico Rapaccini, Mariella Di Marco, Eugenio Caturelli, Marco Zoli, Franco Borzio, Giuseppe Cabibbo, Martina Felder, Antonio Gasbarrini, Rodolfo Sacco, Francesco Giuseppe Foschi, Gabriele Missale, Filomena Morisco, Gianluca Svegliati Baroni, Roberto Virdone, Franco Trevisani and for the Italian Liver Cancer (ITA.LI.CA) Group
Article first published online: 10 APR 2014 | DOI: 10.1002/cncr.28706
In patients with hepatocellular carcinoma, serum levels of α-fetoprotein are influenced by sex, characteristics of chronic liver disease, and features of tumor aggressiveness. These findings confirm the limits of using α-fetoprotein as a clinical aid in patients with known or suspected hepatocellular carcinoma.